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Abstract
Background: Autoimmune sensorineural hearing loss, also known as autoimmune inner ear disease (AIED) is a rare
clinical entity characterized by progressive and bilateral sensorineural hearing loss often accompanied by vestibular
symptoms. Diagnosis is essential as a consistent number of patients show a positive response to steroids alone or in
association with other immunosuppressive drugs. AIED is defined as primary when the disease is limited to the ear,
whereas in up to a third of cases it is associated to other systemic autoimmune diseases such as Behçet disease (BD).
BD is a rare multisystem vasculitis characterized by recurrent oral and genital aphtosis, uveitis, skin lesions, neurological
and vascular manifestations. Clinical presentation is variable thus making the diagnosis difficult in many instances. The
choice of therapy is also limited by the scarceness of high-quality therapy studies.
Case presentation: We present a 15-year-old-boy with six months of history of fever, dizziness, tinnitus and ataxia. He
had a final diagnosis of AIED associated to BD and was successfully treated with the anti-tumor necrosis factor (TNF)-α
adalimumab.
Conclusions: This case report points out to the diagnostic and therapeutic challenges of BD especially when unusual
symptoms are the prominent manifestations of the disease. It also suggests that adalimumab is a good therapeutic
option in children with BD and audiovestibular symptoms.
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Background
Autoimmune sensorineural hearing loss, also known as
autoimmune inner ear disease (AIED) results from dys-
function of the inner ear, the vestibule-cochlear nerve or
the brain processing centres [1]. In most cases AIED is
idiopathic and involves only the ear, however, in about a
third of cases, it occurs in the context of systemic auto-
immune diseases such as Cogan’s syndrome, Wegener’s
granulomatosis, sarcoidosis, juvenile idiopathic arthritis
and Behçet disease (BD) (Table 1) [1, 2]. Treatment usu-
ally includes corticosteroids and immunosuppressive
drugs but refractory cases are described [1].
BD is a rare multisystem vasculitis characterized by re-
current oral and genital aphtosis, uveitis, skin lesions,
neurological and vascular manifestations [3]. BD has an
endemic distribution along the ancient Silk Road, but is
rare in Europe and in the U.S.A [4]. Clinical presentation
is variable thus making the diagnosis difficult in many
instances. A correlation between genetic predisposition
and triggering extrinsic factors has been suggested; in-
deed more than 60 % of BD patients are associated with
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HLA-B51 [5] and some cases may be also associated
with HLA-B52 [6].
Sensorineural hearing loss and vertigo have been de-
scribed in adult patients with BD, but are exceptionally
rare in paediatric age [7].
We report the case of a 15 year-old boy who had re-
current episodes of vertigo and hearing loss that was fi-
nally diagnosed with a BD. All the symptoms resolved
with the administration of the anti-tumor necrosis factor
(TNF)-α drug adalimumab.
Case presentation
A 15 year-old boy of Italian descent presented to our
Department with a six-month history of recurrent epi-
sodes of fever, vomiting, dizziness, headache, tinnitus
and ataxia. He had no significant past medical or family
history. Magnetic resonance imaging (MRI) performed
on day 7 post onset of symptoms excluded cerebral and
brainstem lesions. A vestibular viral neuritis was diag-
nosed and the boy was continuously treated with oral
steroids with partial improvement.
On admission the boy was conscious, his body
temperature was 37°C and blood pressure was within
normal limits (100/60 mm Hg). He had dizziness, hori-
zontal nystagmus which was aggravated by head move-
ments. He was not able to sit or stand up. Romberg’s
sign and head-thrust test were positive. No visual prob-
lems, meningeal signs, clonus or pathologic reflexes
were noted. Both tympanic membranes were normal.
Laboratory tests resulted normal except for a slight
elevation of erythrocyte sedimentation rate (ESR: 40
mm/h) and C-reactive protein (CRP: 4.5 mg/dl); a neu-
trophilic leucocytosis was noted. Cerebrospinal fluid
(CSF) analysis revealed 3 nucleated cells/field, normal
glucose and protein levels and negative tests for Herpes
virus 1-2, Enterovirus and Borrelia Burgdorferi. Cultures
of CSF, blood, urine and throat swabs showed negative
results. Varicella-zoster, Borrelia Burgdorferi, Cyto-
megalovirus and Epstein-Barr virus serology were also
negative. Anti-cochlear and anti-nuclear antibodies
(ANA) were absent. The haplotype HLAB52 was found.
Audiometry revealed bilateral sensorineural hearing
loss. Chest x-ray, abdomen ultrasound and brain MRI
excluded any abnormality. An electroencephalogram
showed normal results.
An autoimmune audio-vestibular disease was sus-
pected, the boy was treated with methylprednisolone
(2 mg/Kg/day). After clinical improvement, a few
weeks later, steroid therapy was gradually tapered and
discontinued.
Two months later, however, febrile episodes recurred
with associated oral ulcers, dizziness and tinnitus. At
that time, eye examination showed anterior uveitis and
retinitis in the right eye.
Colonoscopy and esophagogastroduodenoscopy were
normal whereas endoscopic video capsule showed a few
ulcers surrounded by healthy mucosa in jejunum and
ileum. Abdominal MRI, however, excluded intestinal
Crohn's disease.
The association of oral ulcers, uveitis, recurrent fever
and neuro-vestibular symptoms suggested BD. The pa-
tient was started on intra-ocular steroids, oral colchicine
1 mg/day and continued low-dose oral prednisone.
Three months later, however, a new flare up of disease
was observed. So, the boy was started with adalimumab
at 24 mg/m2 subcutaneously every other week. His
symptoms completely resolved soon after the therapy
was introduced and prednisone was discontinued two
months later.
Follow-up audiometry, laboratory evaluation and ocu-
lar screening recorded normal values.
At two-year follow-up, the boy continues adalimumab
treatment and is symptom free.
Case discussion
To the best of our knowledge, this is the first case de-
scribed of paediatric BD with audio-vestibular manifesta-
tions responding to adalimumab. Our patient initially
presented vertigo, fever and hearing loss, symptoms that
were difficult to classify at a first examination.
Differential diagnosis included a large group of syn-
dromes characterized by dysfunction of the inner ear
causing vertigo and hearing loss (Table 1).
AIED accounts for less than 1 % of all cases of hearing
loss; it has an immune-mediated pathogenesis involving
both innate and adaptive immune system, developing an
immune reaction in the endolymphatic sac, ultimately
leading to the destruction of sensory and supporting
cells within the cochlea. Cytokines such as IL-1, IL-2
and TNF-α and the transcriptor factor NF-kB are
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involved in the immune response [1]. Given the absence
of specific tests, the diagnosis of AIED may be difficult
and is mainly based on the association of appropriate
clinical presentation (bilateral hearing loss with associ-
ated vertigo in about 50 % of cases), exclusion of other
causes, and a positive response to steroid treatment [1].
In every patient who has progressive bilateral sensori-
neural hearing loss with no other explainable cause,
AIED should be considered, a systemic autoimmune dis-
ease associated should be investigated and specific
hematologic tests (complete blood count, ESR, CRP,
ANA e anti-cochlear antibodies, C3 and C4 complement
levels) should be performed. After, a trial with steroids
(1mg/Kg/day of prednisone or methylprednisolone)
should be attempted. However, the overall response rate
to steroids is about 50-70 % of cases; in patients non-
responders to corticosteroids, immunomodulatory agents
such as methotrexate and anti-TNF-α drugs (adalimumab,
etanercept and infliximab) can be used [1].
In our patient, diagnosis was delayed and was possible
only when the classic symptoms of BD disease appeared
and one could assume that the ongoing steroid therapy
contributed to delay the onset of symptoms and there-
fore the correct diagnosis.
The diagnostic criteria for BD were defined by the
International Study Group (ISG) for BD in 1990, and in-
clude the presence of recurrent oral ulceration, with at
least three episodes over 12 months, in addition to two
of the following features: recurrent genital ulcers, eye
lesions, skin lesions and a positive pathergy test [8].
Recently new criteria have been developed in order to
facilitate the diagnosis both in adults and in paediatric
patients [2, 9]. Indeed our patient didn’t fulfil the ISG
criteria, whereas he presented the criteria for the diagno-
sis of paediatric BD (neurological signs, recurrent oral
aphthosis and ocular involvement) [9]. In addition he
carried the allele HLA-B52, an antigen that has also
been associated with BD [6].
BD treatment includes colchicine, corticosteroids, dap-
sone and immunosuppressive drugs in severe cases. The
choice of therapy, however, is limited by the scarceness of
high-quality therapy trials and is based largely on case re-
ports, case series and few randomized clinical trials [10].
High levels of TNF-α and its soluble receptor have
been found in the serum and aqueous humor of patients
with active BD [11]. For this reason, anti-TNF-α treat-
ment has been increasingly reported in BD, especially in
refractory severe disease [12, 13]. Our patient presented
a rapid and sustained response to adalimumab treat-
ment. Complete resolution of audio-vestibular symp-
toms, ocular inflammation and oral ulcerations was
noted; furthermore febrile attacks subsided as soon as
adalimumab treatment was started. Besides, no adverse
events were observed in two years follow-up.
Conclusions
This case report points out to the diagnostic and thera-
peutic challenges of BD especially when unusual symp-
toms are the prominent manifestations of the disease. It
also suggests that adalimumab is a good therapeutic op-
tion in children with BD and audiovestibular symptoms.
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